RENB
Renovaro Inc
$
0.309
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.337
Open
0.337
VWAP
0.31
Vol
595.70K
Mkt Cap
53.17M
Low
0.305
Amount
186.39K
EV/EBITDA(TTM)
--
Total Shares
153.93M
EV
57.52M
EV/OCF(TTM)
--
P/S(TTM)
--
Renovaro Inc. specializes in cancer diagnostics and therapeutics powered by artificial intelligence (AI). The Company operates through two subsidiaries: Renovaro Biosciences, Inc. (Renovaro Biosciences) and Renovaro Cube. Renovaro Biosciences is a biotechnology company intending to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections. Renovaro Cube is an AI-driven healthcare technology company focusing on the earliest possible detection of cancer and its recurrence. Renovaro Cube has developed an AI platform that analyzes genetics using Explainable AI to provide earlier and more accurate cancer diagnosis. This platform uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.
Show More
Valuation Metrics
The current forward P/E ratio for Renovaro Inc (RENB.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Renovaro Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q3
N/A
Total Revenue
FY2025Q3
YoY :
-52.54%
-4.16M
Operating Profit
FY2025Q3
YoY :
-100.32%
189.18K
Net Income after Tax
FY2025Q3
YoY :
-100.00%
0.00
EPS - Diluted
FY2025Q3
YoY :
-43.64%
-1.49M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
RENB News & Events
Events Timeline
2025-07-17 (ET)
2025-07-17
09:29:45
Renovaro BioSciences announces publication of study on dendritic cell therapy
2025-07-09 (ET)
2025-07-09
08:29:36
Renovaro BioSciences strengthens balance sheet through debt conversion
2025-06-30 (ET)
2025-06-30
09:23:42
Renovaro BioSciences launches AI-based neurotoxin countermeasure initiative
Sign Up For More Events
Sign Up For More Events
News
3.5
06-10NewsfilterSmart Healthcare Is Taking Over. Here's Where the Money's Headed
3.5
06-10PRnewswireSmart Healthcare Is Taking Over. Here's Where the Money's Headed
9.0
06-03NewsfilterRenovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
Sign Up For More News
People Also Watch
OCFT
OneConnect Financial Technology Co Ltd
7.490
USD
+0.54%
SVII
Spring Valley Acquisition Corp II
11.840
USD
-0.08%
TNYA
Tenaya Therapeutics Inc
0.833
USD
-3.70%
KLXE
KLX Energy Services Holdings Inc
1.890
USD
-4.06%
SKLZ
Skillz Inc
8.520
USD
+4.80%
WMPN
William Penn Bancorp
0
USD
-0.24%
LGO
Largo Inc
1.590
USD
-0.63%
ACNT
Ascent Industries Co
12.960
USD
-0.99%
BZFD
BuzzFeed Inc
2.380
USD
-2.06%
ENTA
Enanta Pharmaceuticals Inc
7.400
USD
+0.82%
FAQ
What is Renovaro Inc (RENB) stock price today?
The current price of RENB is 0.3089 USD — it has decreased -5.22 % in the last trading day.
What is Renovaro Inc (RENB)'s business?
What is the price predicton of RENB Stock?
What is Renovaro Inc (RENB)'s revenue for the last quarter?
What is Renovaro Inc (RENB)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Renovaro Inc (RENB)'s fundamentals?
How many employees does Renovaro Inc (RENB). have?